Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Castle Biosciences stock (CSTL)

Buy Castle Biosciences stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Castle Biosciences is a diagnostics & research business based in the US. Castle Biosciences shares (CSTL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $29.12 – a decrease of 6.64% over the previous week. Castle Biosciences employs 710 staff and has a trailing 12-month revenue of around $311.9 million.

Our top picks for where to buy Castle Biosciences stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Get up to $1,000 in stock when you fund a new account within 30 days
  • Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%

How to buy Castle Biosciences stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CSTL. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Castle Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.8 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.3 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a complimentary access to financial planners.
Robinhood
Finder Score: 4.6 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Public.com
Finder Score: 4.4 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Castle Biosciences stock price (NASDAQ: CSTL)

Use our graph to track the performance of CSTL stocks over time.

Castle Biosciences shares at a glance

Information last updated 2024-12-11.
Latest market close$29.12
52-week range$16.97 - $35.84
50-day moving average $31.22
200-day moving average $25.36
Wall St. target price$41.56
PE ratio 140.381
Dividend yield N/A
Earnings per share (TTM) $0.21

Is it a good time to buy Castle Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Castle Biosciences price performance over time

Historical closes compared with the close of $29.48 from 2024-12-11

1 week (2024-12-06) -5.48%
1 month (2024-11-13) -7.30%
3 months (2024-09-13) -5.45%
6 months (2024-06-13) 29.98%
1 year (2023-12-13) 43.45%
2 years (2022-12-13) 23.50%
3 years (2021-12-13) 40.42
5 years (2019-12-13) 29.5

Is Castle Biosciences stock undervalued or overvalued?

Valuing Castle Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Castle Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Castle Biosciences's P/E ratio

Castle Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 140x. In other words, Castle Biosciences shares trade at around 140x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Castle Biosciences's EBITDA

Castle Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12.4 million.

The EBITDA is a measure of a Castle Biosciences's overall financial performance and is widely used to measure a its profitability.

Castle Biosciences financials

Revenue TTM $311.9 million
Operating margin TTM 5.92%
Gross profit TTM $105 million
Return on assets TTM -0.14%
Return on equity TTM 1.47%
Profit margin 1.95%
Book value $15.77
Market Capitalization $825.7 million

TTM: trailing 12 months

Castle Biosciences share dividends

We're not expecting Castle Biosciences to pay a dividend over the next 12 months.

Castle Biosciences share price volatility

Over the last 12 months, Castle Biosciences's shares have ranged in value from as little as $16.965 up to $35.84. A popular way to gauge a stock's volatility is its "beta".

CSTL.US volatility(beta: 0.99)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Castle Biosciences's is 0.985. This would suggest that Castle Biosciences's shares are less volatile than average (for this exchange).

Castle Biosciences overview

Castle Biosciences, Inc. , a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. .

Frequently asked questions

null
What percentage of Castle Biosciences is owned by insiders or institutions?
Currently 3.213% of Castle Biosciences shares are held by insiders and 94.548% by institutions.
How many people work for Castle Biosciences?
Latest data suggests 710 work at Castle Biosciences.
When does the fiscal year end for Castle Biosciences?
Castle Biosciences's fiscal year ends in December.
Where is Castle Biosciences based?
Castle Biosciences's address is: 505 South Friendswood Drive, Friendswood, TX, United States, 77546
What is Castle Biosciences's ISIN number?
Castle Biosciences's international securities identification number is: US14843C1053
What is Castle Biosciences's CUSIP number?
Castle Biosciences's Committee on Uniform Securities Identification Procedures number is: 14843C105

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site